Trial Profile

To Assess Mechanisms Linking Immune Checkpoint Inhibitor Pharmacokinetics and Outcomes in Cancer Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Cancer; Non-small cell lung cancer; Renal cell carcinoma
Focus Pharmacokinetics

Most Recent Events

21 May 2024 New trial record
29 Mar 2024 Results assessing minimal sampling scheme using pre-dose and within 30 minutes post-dose across 4 consecutive cycles of treatment to estimate baseline and time-varying clearance and to assess underlying mechanisms linking ICI CL0 and Fc Receptors in cancer patients presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com